USP51 and cancer: Furthermore, juxtacrine interaction by ubiquitin-specific peptidase 51/programmed death ligand one/integrin beta-1 has been demonstrated by Li et al. in NSCLC to the malignant tumor progression and therapeutic resistance in NSCLC (Li et al., 2023).